Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.

Post hoc analyses by patient subgroups At week 28, patients stratified by prior and non-prior anti-TNF use showed similar ACR20, ACR50 and ACR70 response rates in the placebo → CZP and CZP → CZP groups, although there was a numerical trend for slightly higher response rates in the anti-TNF naïve patients (Fig. 3a ).

also in 723 other papers